In the deal, DePuy is offloading its Prodisc-C, Prodisc-L, Prodisc-C Vivo, Prodisc-C Nova, Prodisc-O and Discover cervical and lumbar artificial disc systems to Centinel Spine, according to the report.
The Prodisc-C and Prodisc-L are the only 2 products which have approval in the US, according to OrthoWorld, and Centinel plans to launch clinical studies as it pursues FDA approval of the other devices it acquired.
Centinel spine is reportedly focusing on the US and Australian markets, but plans to launch the portfolio into other markets as well.
The acquisition is set to close during the 4th quarter, according to the report, and will leave DePuy Synthes with only the Inmotion lumbar disc.
Last June, Centinel Spine said it won Australian Therapeutic Goods Administration clearance for its Stalif L no-profile lateral lumbar integrated interbody system.